Tirzepatide vs. Semaglutide – Which Is Better for Weight Loss?
This article compares the pharmacology of two incretin molecules using evidence from registration trials.
This article compares the pharmacology of two incretin molecules using evidence from registration trials. It does not recommend treatment or provide use regimens. That distinction matters because all efficacy data cited below come from studies of prescription medicinal products administered under medical supervision. They are not data about research materials available outside the pharmacy supply chain. A separate section explains this difference because it is frequently overlooked in articles on the subject.
All substances discussed in this article are research compounds and are not intended for human consumption. Descriptions of their activity are based solely on laboratory findings and experimental observations, not on clinical testing.
Two molecules, two mechanisms
Semaglutide: a GLP-1 receptor agonist
Semaglutide is an analogue of glucagon-like peptide 1 (GLP-1), an incretin hormone released by the intestine in response to a meal. Activating the GLP-1 receptor produces several parallel effects: glucose-dependent insulin secretion, reduced glucagon secretion, slower gastric emptying and effects on central appetite-regulation pathways in the hypothalamus. The physiology of this system and its pharmacological implications have been described in detail in reviews by Drucker (Drucker, 2018, PMID 29617641) and (Drucker, 2022, PMID 34626851).
Tirzepatide: a dual GIP and GLP-1 agonist
Tirzepatide, development code LY3298176, acts on two receptors at the same time: GLP-1 and GIP, or glucose-dependent insulinotropic polypeptide. GIP is the other principal incretin and was long regarded as a less promising therapeutic target. The molecule’s development from discovery to early proof of concept was described in Molecular Metabolism (Coskun et al., 2018, PMID 30473097). A broader overview of this molecule is available in our separate article on tirzepatide and its research profile.
The fundamental difference between these molecules is therefore the number of receptors they activate, not “strength” in the everyday sense. Not all effects combine as one might expect. In a pharmacodynamic study, tirzepatide’s delay of gastric emptying was transient and similar to that observed with selective, long-acting GLP-1 agonists (Urva et al., 2020, PMID 32519795).
What did the registration trials show?
The results below come from clinical trials in which participants received registered medicinal products. Dosing regimens are deliberately omitted because those belong to the product information and to decisions made by the treating physician.
SURPASS-2: the only direct comparison
SURPASS-2 compared both molecules head to head in participants with type 2 diabetes. Across the tirzepatide dose groups, glycated haemoglobin fell by 2.01 to 2.30 percentage points, compared with 1.86 percentage points for semaglutide. Differences in body-weight reduction favouring tirzepatide ranged from 1.9 kg to 5.5 kg, depending on the group compared (Frías et al., 2021, PMID 34170647). The most common adverse events in both groups were gastrointestinal.
STEP 1 and SURMOUNT-1: body weight in separate trials
STEP 1 enrolled participants with overweight or obesity without diabetes. After 68 weeks, mean body-weight change was -14.9% with semaglutide and -2.4% with placebo (Wilding et al., 2021, PMID 33567185). In SURMOUNT-1, which enrolled participants with obesity, mean body-weight change after 72 weeks ranged from -15.0% to -20.9% across tirzepatide dose groups, compared with -3.1% with placebo (Jastreboff et al., 2022, PMID 35658024).
A methodological qualification is essential here. STEP 1 and SURMOUNT-1 were separate trials with different populations, durations and protocols. Presenting -20.9% and -14.9% as a direct comparison between the two molecules is not methodologically valid. SURPASS-2 remains the direct comparison, and it was conducted in a population with type 2 diabetes rather than in people pursuing weight reduction. In other words, the literature suggests an advantage for dual agonism in the studied endpoints, but this difference is much better documented for glycaemic control than for weight reduction alone.
Cardiovascular endpoints
Semaglutide has been studied for cardiovascular events in participants with obesity but without diabetes (Lincoff et al., 2023, PMID 37952131). A separate trial examined tirzepatide in people with obesity and coexisting type 2 diabetes (Garvey et al., 2023, PMID 37385275).
The central distinction: prescription medicine versus research material
This is the most important part of the article and the point missing from many comparisons available online.
Every figure cited above comes from trials in which participants received registered medicinal products with verified identity, content and purity. Treatment took place under medical supervision, adverse events were monitored, and exclusion criteria were applied. These results describe the behaviour of a specific medicine in a specific population.
A research-status material sold as a reagent rather than a medicine is not the same object. It differs in regulatory status, intended purpose and the absence of medical oversight for human use. Efficacy data from registration trials cannot be transferred to such a material because those data were not generated with it. This is not an editorial formality. A clinical trial measures a medicine administered under defined conditions, not a molecule detached from those conditions.
The practical conclusion is unambiguous: incretin analogues sold as research materials are not “non-prescription fat burners”. Therapeutic equivalents of the molecules discussed here are prescription medicines, and any decision to use them, including assessment of contraindications and monitoring, belongs to a physician.
Regulatory status and anti-doping note
Semaglutide and tirzepatide are active substances in registered prescription medicines intended for specific indications under medical supervision. Research materials containing incretin analogues are not medicinal products, are not dietary supplements and are not intended for human consumption.
WADA status. GLP-1 analogues have not been listed as prohibited substances on the Prohibited List. They are, however, of interest to the World Anti-Doping Agency and have been included in its Monitoring Program, which tracks patterns of their presence in samples. The status of this compound class remains under evaluation and may change. An athlete registered in ADAMS should therefore check the current Prohibited List and Monitoring Program rather than rely on an article, including this one.
Harm reduction
Three points should be clarified regardless of the sporting context. First, the adverse-event profile observed in registration trials was mainly gastrointestinal and was monitored by a research team; outside such supervision, nobody systematically records those events. Second, clinical trials applied exclusion criteria covering specific health conditions; outside a trial, nobody verifies those criteria. Third, the identity and purity of the substances used in the trials were confirmed through the medicine manufacturer’s documentation. For a research material, the closest corresponding document is the certificate of analysis for the specific batch.
Frequently asked questions
How does tirzepatide differ from semaglutide?
They activate different numbers of receptors. Semaglutide is a GLP-1 receptor agonist, while tirzepatide acts on both GIP and GLP-1 receptors. This mechanistic distinction results in different profiles in clinical trials. The difference is best documented for glycaemic control because the direct comparison, SURPASS-2, was conducted in people with type 2 diabetes.
Can STEP 1 and SURMOUNT-1 results be compared directly?
No. They are separate trials with different populations, durations and protocols. Treating their percentage results as a direct comparison between the molecules is methodologically invalid.
Do the efficacy data apply to research materials sold outside pharmacies?
No. Every efficacy result cited here comes from trials of registered prescription medicines conducted under medical supervision. Research-status material is a separate object in terms of regulation and intended purpose.
What is the status of these compounds in sport?
GLP-1 analogues have not been listed as prohibited substances, but they are covered by WADA’s Monitoring Program and their status remains under evaluation. The current position should be checked in the latest WADA documents.
Summary
Semaglutide and tirzepatide have different mechanisms. The former is a GLP-1 receptor agonist; the latter acts on both GIP and GLP-1 receptors. In the only direct comparison, conducted in participants with type 2 diabetes, tirzepatide produced greater reductions in glycated haemoglobin and body weight. The obesity trials STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide used separate protocols and are not a direct comparison, which matters when interpreting percentage figures circulated online. The most important qualification concerns what was actually studied: all cited data were generated using registered prescription medicines administered under medical supervision and do not describe research-status materials.
Product documentation
Research-material pages with batch-specific analytical documentation: SEMA G vial, SEMA G PEN, GLP1+GIP vial, Tirzepatide 5 mg and GLP1+GIP pen. Other items in this class are collected in the weight loss peptides category. These materials are intended solely for research applications.
References
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PMID: 30473097
- Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020;22(10):1886-1891. PMID: 32519795
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. PMID: 37385275
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641
- Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351. PMID: 34626851